PsychRounds: The Psychiatry Podcast [SPARI] - Vilazodone (Viibryd)
6 snips
Feb 2, 2024 Dive into the world of Vilazodone, also known as Viibryd, exploring its unique properties as a serotonin partial agonist and reuptake inhibitor. Discover how it compares to Buspirone, particularly in reducing pill burden and addressing sexual side effects. The discussion also highlights the FDA's opinions on its marketing claims and its effectiveness in treating depression. With insights into new developments like Jepron and advancements in antidepressant efficacy, the conversation is a deep dive into the evolving landscape of psychiatric treatment.
AI Snips
Chapters
Transcript
Episode notes
Vilazodone's Unique Mechanism
- Vilazodone is a SPARI, combining serotonin transporter inhibition with 5-HT1A partial agonism.
- This creates a hybrid effect similar to combining escitalopram with buspirone in one drug.
Limited FDA Approvals and Efficacy
- Vilazodone is FDA-approved only for major depressive disorder, not anxiety.
- Studies show it is not more effective than SSRIs like citalopram for depression.
Convenience in Prescribing Vilazodone
- Prescribe Vilazodone for patients who want fewer pills or once-daily dosing instead of multiple medications.
- It offers convenience over separate escitalopram and buspirone regimens.